Literature DB >> 24705119

Transplantation-free survival and interventions at 3 years in the single ventricle reconstruction trial.

Jane W Newburger1, Lynn A Sleeper2, Peter C Frommelt2, Gail D Pearson2, William T Mahle2, Shan Chen2, Carolyn Dunbar-Masterson2, Seema Mital2, Ismee A Williams2, Nancy S Ghanayem2, Caren S Goldberg2, Jeffrey P Jacobs2, Catherine D Krawczeski2, Alan B Lewis2, Sara K Pasquali2, Christian Pizarro2, Peter J Gruber2, Andrew M Atz2, Svetlana Khaikin2, J William Gaynor2, Richard G Ohye2.   

Abstract

BACKGROUND: In the Single Ventricle Reconstruction (SVR) trial, 1-year transplantation-free survival was better for the Norwood procedure with right ventricle-to-pulmonary artery shunt (RVPAS) compared with a modified Blalock-Taussig shunt (MBTS). At 3 years, we compared transplantation-free survival, echocardiographic right ventricular ejection fraction, and unplanned interventions in the treatment groups. METHODS AND
RESULTS: Vital status and medical history were ascertained from annual medical records, death indexes, and phone interviews. The cohort included 549 patients randomized and treated in the SVR trial. Transplantation-free survival for the RVPAS versus MBTS groups did not differ at 3 years (67% versus 61%; P=0.15) or with all available follow-up of 4.8±1.1 years (log-rank P=0.14). Pre-Fontan right ventricular ejection fraction was lower in the RVPAS group than in the MBTS group (41.7±5.1% versus 44.7±6.0%; P=0.007), and right ventricular ejection fraction deteriorated in RVPAS (P=0.004) but not MBTS (P=0.40) subjects (pre-Fontan minus 14-month mean, -3.25±8.24% versus 0.99±8.80%; P=0.009). The RVPAS versus MBTS treatment effect had nonproportional hazards (P=0.004); the hazard ratio favored the RVPAS before 5 months (hazard ratio=0.63; 95% confidence interval, 0.45-0.88) but the MBTS beyond 1 year (hazard ratio=2.22; 95% confidence interval, 1.07-4.62). By 3 years, RVPAS subjects had a higher incidence of catheter interventions (P<0.001) with an increasing HR over time (P=0.005): <5 months, 1.14 (95% confidence interval, 0.81-1.60); from 5 months to 1 year, 1.94 (95% confidence interval, 1.02-3.69); and >1 year, 2.48 (95% confidence interval, 1.28-4.80).
CONCLUSIONS: By 3 years, the Norwood procedure with RVPAS compared with MBTS was no longer associated with superior transplantation-free survival. Moreover, RVPAS subjects had slightly worse right ventricular ejection fraction and underwent more catheter interventions with increasing hazard ratio over time. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00115934.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  Norwood procedures; cardiac surgical procedures; heart defects, congenital; heart diseases; heart ventricles

Mesh:

Year:  2014        PMID: 24705119      PMCID: PMC4029928          DOI: 10.1161/CIRCULATIONAHA.113.006191

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  21 in total

1.  Comparison of right ventricle to pulmonary artery conduit and modified Blalock-Taussig shunt hemodynamics after the Norwood operation.

Authors:  Richard G Ohye; Achiau Ludomirsky; Eric J Devaney; Edward L Bove
Journal:  Ann Thorac Surg       Date:  2004-09       Impact factor: 4.330

2.  Does the shunt type determine mid-term outcome after Norwood operation?

Authors:  Joachim Photiadis; Nicodème Sinzobahamvya; Christoph Haun; Martin Schneider; Peter Zartner; Ehrenfried Schindler; Boulos Asfour; Viktor Hraska
Journal:  Eur J Cardiothorac Surg       Date:  2012-02-20       Impact factor: 4.191

Review 3.  Pathophysiology of collateral development.

Authors:  Matthias Heil; Wolfgang Schaper
Journal:  Coron Artery Dis       Date:  2004-11       Impact factor: 1.439

4.  Postoperative assessment of a modified surgical approach to repair of tetralogy of Fallot. Long-term follow-up.

Authors:  N H Atallah-Yunes; R E Kavey; E L Bove; F C Smith; D A Kveselis; C J Byrum; W E Gaum
Journal:  Circulation       Date:  1996-11-01       Impact factor: 29.690

5.  Intermediate-term mortality and cardiac transplantation in infants with single-ventricle lesions: risk factors and their interaction with shunt type.

Authors:  James S Tweddell; Lynn A Sleeper; Richard G Ohye; Ismee A Williams; Lynn Mahony; Christian Pizarro; Victoria L Pemberton; Peter C Frommelt; Scott M Bradley; James F Cnota; Jennifer Hirsch; Paul M Kirshbom; Jennifer S Li; Nancy Pike; Michael Puchalski; Chitra Ravishankar; Jeffrey P Jacobs; Peter C Laussen; Brian W McCrindle
Journal:  J Thorac Cardiovasc Surg       Date:  2012-02-15       Impact factor: 5.209

6.  Systemic-to-pulmonary collateral flow, as measured by cardiac magnetic resonance imaging, is associated with acute post-Fontan clinical outcomes.

Authors:  Andrew C Glatz; Jonathan J Rome; Adam J Small; Matthew J Gillespie; Yoav Dori; Matthew A Harris; Marc S Keller; Mark A Fogel; Kevin K Whitehead
Journal:  Circ Cardiovasc Imaging       Date:  2012-01-06       Impact factor: 7.792

7.  Hospital stays, hospital charges, and in-hospital deaths among infants with selected birth defects--United States, 2003.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2007-01-19       Impact factor: 17.586

8.  Design and rationale of a randomized trial comparing the Blalock-Taussig and right ventricle-pulmonary artery shunts in the Norwood procedure.

Authors:  Richard G Ohye; J William Gaynor; Nancy S Ghanayem; Caren S Goldberg; Peter C Laussen; Peter C Frommelt; Jane W Newburger; Gail D Pearson; Sarah Tabbutt; Gil Wernovsky; Lisa M Wruck; Andrew M Atz; Steve D Colan; James Jaggers; Brian W McCrindle; Ashwin Prakash; Michael D Puchalski; Lynn A Sleeper; Mario P Stylianou; Lynn Mahony
Journal:  J Thorac Cardiovasc Surg       Date:  2008-05-19       Impact factor: 5.209

9.  Cause, timing, and location of death in the Single Ventricle Reconstruction trial.

Authors:  Richard G Ohye; Julie V Schonbeck; Pirooz Eghtesady; Peter C Laussen; Christian Pizarro; Peter Shrader; Deborah U Frank; Eric M Graham; Kevin D Hill; Jeffrey P Jacobs; Kirk R Kanter; Joel A Kirsh; Linda M Lambert; Alan B Lewis; Chitra Ravishankar; James S Tweddell; Ismee A Williams; Gail D Pearson
Journal:  J Thorac Cardiovasc Surg       Date:  2012-08-15       Impact factor: 5.209

10.  Elevated vascular endothelial growth factor levels are associated with aortopulmonary collateral vessels in patients before and after the Fontan procedure.

Authors:  Yoshiki Mori; Makiko Shoji; Toshio Nakanishi; Takanari Fujii; Makoto Nakazawa
Journal:  Am Heart J       Date:  2007-06       Impact factor: 4.749

View more
  45 in total

1.  Stem cells on a new stage: Treatment of hypoplastic left heart syndrome.

Authors:  Sunjay Kaushal; Brody Wehman
Journal:  J Thorac Cardiovasc Surg       Date:  2015-07-10       Impact factor: 5.209

2.  Reduced cortical volume and thickness and their relationship to medical and operative features in post-Fontan children and adolescents.

Authors:  Christopher G Watson; Christian Stopp; David Wypij; Jane W Newburger; Michael J Rivkin
Journal:  Pediatr Res       Date:  2017-02-03       Impact factor: 3.756

3.  Maladaptive aortic properties after the Norwood procedure: An angiographic analysis of the Pediatric Heart Network Single Ventricle Reconstruction Trial.

Authors:  Sarah T Plummer; Christoph P Hornik; Hamilton Baker; Gregory A Fleming; Susan Foerster; M Eric Ferguson; Andrew C Glatz; Russel Hirsch; Jeffrey P Jacobs; Kyong-Jin Lee; Alan B Lewis; Jennifer S Li; Mary Martin; Diego Porras; Wolfgang A K Radtke; John F Rhodes; Julie A Vincent; Jeffrey D Zampi; Kevin D Hill
Journal:  J Thorac Cardiovasc Surg       Date:  2016-04-14       Impact factor: 5.209

4.  Factors affecting Fontan length of stay: Results from the Single Ventricle Reconstruction trial.

Authors:  Chitra Ravishankar; Eric Gerstenberger; Lynn A Sleeper; Andrew M Atz; Jeremy T Affolter; Timothy J Bradley; J William Gaynor; Bryan H Goldstein; Heather T Henderson; Jeffrey P Jacobs; Alan B Lewis; Carolyn Dunbar-Masterson; Shaji C Menon; Victoria L Pemberton; Christopher J Petit; Nancy A Pike; Christian Pizarro; Kurt R Schumacher; Ismee A Williams; Jane W Newburger
Journal:  J Thorac Cardiovasc Surg       Date:  2015-09-28       Impact factor: 5.209

5.  A Shift in Focus.

Authors:  Ra-Id Abdulla
Journal:  Pediatr Cardiol       Date:  2018-04-10       Impact factor: 1.655

6.  Heart failure after the Norwood procedure: An analysis of the Single Ventricle Reconstruction Trial.

Authors:  William T Mahle; Chenwei Hu; Felicia Trachtenberg; JonDavid Menteer; Steven J Kindel; Anne I Dipchand; Marc E Richmond; Kevin P Daly; Heather T Henderson; Kimberly Y Lin; Michael McCulloch; Ashwin K Lal; Kurt R Schumacher; Jeffrey P Jacobs; Andrew M Atz; Chet R Villa; Kristin M Burns; Jane W Newburger
Journal:  J Heart Lung Transplant       Date:  2018-02-16       Impact factor: 10.247

7.  Transplant-Free Survival and Interventions at 6 Years in the SVR Trial.

Authors:  Jane W Newburger; Lynn A Sleeper; J William Gaynor; Danielle Hollenbeck-Pringle; Peter C Frommelt; Jennifer S Li; William T Mahle; Ismee A Williams; Andrew M Atz; Kristin M Burns; Shan Chen; James Cnota; Carolyn Dunbar-Masterson; Nancy S Ghanayem; Caren S Goldberg; Jeffrey P Jacobs; Alan B Lewis; Seema Mital; Christian Pizarro; Aaron Eckhauser; Paul Stark; Richard G Ohye
Journal:  Circulation       Date:  2018-02-01       Impact factor: 29.690

Review 8.  Hypoplastic left heart syndrome: current perspectives.

Authors:  Christopher E Greenleaf; J Miguel Urencio; Jorge D Salazar; Ali Dodge-Khatami
Journal:  Transl Pediatr       Date:  2016-07

9.  Hypoplastic Left Heart Syndrome: Exploring a Paradigm Shift in Favor of Surgery.

Authors:  Erin A Paul; Kristina Orfali; Thomas J Starc
Journal:  Pediatr Cardiol       Date:  2016-08-27       Impact factor: 1.655

Review 10.  Rationale and methodology of a collaborative learning project in congenital cardiac care.

Authors:  Michael J Wolf; Eva K Lee; Susan C Nicolson; Gail D Pearson; Madolin K Witte; Jeryl Huckaby; Michael Gaies; Lara S Shekerdemian; William T Mahle
Journal:  Am Heart J       Date:  2016-01-23       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.